Cognito Therapeutics, Inc.

We’re excited to present multiple poster presentations for our disease-modifying therapy Spectris™ in patients with Alzheimer’s Disease, at the 17th CTAD Clinical Trials on Alzheimer's Disease conference taking place in Madrid, Spain, and online, October 29 – November 1, 2024. “We’re excited to present this new clinical data at CTAD, which demonstrates the potential of Spectris™ to preserve both brain function and structure in Alzheimer’s disease patients,” said Christian Howell, CEO of Cognito Therapeutics. “Our recruitment strategies for the HOPE trial have enabled us to evaluate a diverse and representative Alzheimer’s population, and we remain focused on advancing our novel, non-invasive disease-modifying therapy for Alzheimer’s patients.” Read the release: 👇👇 https://lnkd.in/eBmBxt4W

Alzheimer’s & Other Neurodegenerative Diseases: Advances in Diagnostic and Therapeutic Treatment Has Been Slow – But is There Light at the End of the Tunnel? 📍 Biotech Showcase 🌍 San Francisco, CA 📆 January 14, 2025 🕖 8:00 – 9:00   Moderator: Karen Bettauer Harris   Panelists: Maha Radhakrishnan Abraham (Abe) C. Christian Howell Olga Danilchanka Find out what else is on the agenda >> https://lnkd.in/euTRssxz   #BiotechShowcase #SanFrancisco Demy-Colton

Julia Leach is Director of Translational Research at Cognito, and was recently featured as one of Oregon Health & Science University's biomedical engineering alumni whose work as Ph.D. students led to discoveries that will change #healthcare for the better. Her journey, from doctoral research at Oregon Health & Science University to recognition as a Business Insider “Top 30 Under 40” healthcare leader, is a testament to her constant learning, adaptation, persistence, and courage. Her advice? “Perseverance, resilience, and humility are essential. Lean on your peers, embrace failure, and devote yourself to a greater purpose. Lean on your peers and colleagues – a collaborative spirit and diverse perspectives are essential for success. That’s what inspires and anchors me.” At Cognito, we’re inspired by Julia’s commitment to transforming the lives of patients with #Alzheimers disease. 🌟 #BiomedicalEngineering #Innovation #NeurodegenerativeCare #WomenInSTEM #HealthcareLeadership Read the article: https://lnkd.in/egTxYN2a

This week’s podcast leaders are leveraging collaboration to build stronger teams, foster trust, and inspire change.  Thanks to all for participating. Check them out below.  Building Trust: Steve Olenski, Chief Marketing Officer at Stan Ventures, explored how consistent messaging and authentic engagement build trust between brands and consumers. Leading with the ABCs: Nora Osman, CEO of Norvana, joined Christopher Kunney on the Straight Outta Health IT podcast to share how authenticity, boldness, and compassion empower teams to innovate and collaborate. Innovating Together: Christian Howell, CEO of Cognito Therapeutics, Inc., revealed how collaboration across researchers, payers, and regulators is paving the way for non-invasive Alzheimer’s treatments. Creating Community: Heather Colicchio, Founder and President of AADOM | American Association of Dental Office Management, joined Jonathan Levine and Mariya Filipova on the Think Oral podcast to discuss the power of connecting dental office managers to share knowledge and solve challenges together. Shared Accountability: Scott Paddock, CEO of Wondr Health, showcased how his company ties its success to user outcomes, fostering collaboration between employers and employees to improve health outcomes. Let’s continue to prioritize collaboration in everything we do! 🚀 📬 Subscribe: https://lnkd.in/ge-_UFpk

Today, we want to express our heartfelt gratitude to Mike Zuendel for sharing his remarkable and inspiring journey living with Alzheimer’s Disease at our recent all employees company meeting. Mike’s advocacy and efforts to change the narrative surrounding cognitive impairment, through the team at Initiative to Change the "D-Word", have been nothing short of extraordinary. In particular, his mission to eliminate the use of the word “dementia” when referring to individuals with cognitive challenges has resonated deeply with us. At Cognito, we are committed to honoring Mike’s vision. Moving forward, we pledge to remove the word “dementia” from our lexicon, embracing language that reflects dignity, respect, and humanity. We also encourage our peers in the field—especially those developing therapies for neurodegenerative diseases—to join us in this important initiative. Together, we can reshape how society understands and discusses cognitive impairment. Thank you, Mike, and your remarkable wife and partner Brooks, for your courage, advocacy, and vision. You are truly making a difference.

Today, we want to express our heartfelt gratitude to Mike Zuendel for sharing his remarkable and inspiring journey living with Alzheimer’s Disease at our recent all employees company meeting. Mike’s advocacy and efforts to change the narrative surrounding cognitive impairment, through the team at Initiative to Change the "D-Word", have been nothing short of extraordinary. In particular, his mission to eliminate the use of the word “dementia” when referring to individuals with cognitive challenges has resonated deeply with us. At Cognito, we are committed to honoring Mike’s vision. Moving forward, we pledge to remove the word “dementia” from our lexicon, embracing language that reflects dignity, respect, and humanity. We also encourage our peers in the field—especially those developing therapies for neurodegenerative diseases—to join us in this important initiative. Together, we can reshape how society understands and discusses cognitive impairment. Thank you, Mike, and your remarkable wife and partner Brooks, for your courage, advocacy, and vision. You are truly making a difference.

Christian brings more than 20 years of expertise in medical devices, where he navigated responsibilities in business development, commercial leadership, product management, market development, and strategy. Prior to joining Cognito Therapeutics, Inc., he was Senior Vice President and General Manager of Aetion’s Medical Device and Diagnostic Group. In this role, Howell was responsible for the commercialization of Aetion’s real-world evidence platform to the medical device and diagnostics industry. During his nearly 15 year tenure at Medtronic, Christian led Medtronic’s Value-Based Health Care Partnerships organization, as well as P&L responsibility for Medtronic’s Integrated Health Solutions program to improve delivery of care and patient experience with partner health systems. Recognized as a forward-thinking industry leader in value-based healthcare, Howell has presented on payment system transformation and partnership strategies with healthcare professionals around the world. Howell is a former Officer in the United States Navy and holds a Bachelor of Science degree from Tulane University. Meet Christian Howell @ #Sachs_NIF More Info @ https://lnkd.in/dHgcp4fq #Neuroscience #Neurotech #NeurologyInnovation #BrainHealth #CNSDisorders #NeurologicalDiseases #ADPD #Neuropsychiatry #PsychedelicResearch #NeuroTechInvestment #Biotech #MedicalInnovation #NeuroscienceForum #NeuroInvestment #NextGenMedicine #NeuroscienceResearch #MentalHealthInnovation #BiotechIndustry

Non-invasive neurostimulation technology can significantly slow #cognitive and functional decline in Alzheimer's patients by stimulating brain activity with a new approach. I had the pleasure of talking with Christian Howell about the groundbreaking work Cognito Therapeutics, Inc. is doing to help slow cognitive decline in Alzheimer's patients using noninvasive neurostimulation #technology. In this episode, Christian also shares insights on the current landscape of Alzheimer’s treatments and his vision for the future of #neurotherapeutics therapy. Tune in to discover the future of non-invasive neurostimulation and the benefits this new technology could bring to Alzheimer's patients! Click this link to listen to the entire episode and to check the show notes: https://lnkd.in/epxwMyQi #podcast #alzheimer #patients #treatment

🧠🔍 Advancing Alzheimer’s and Parkinson’s Care! Join us for the ‘Innovation in AD/PD & Other Cognitive Disorders Panel’ at the #Sachs_NIF on January 12th, 2025, at the Marines’ Memorial Club, San Francisco. Explore the forefront of research and treatment innovations for Alzheimer’s Disease, Parkinson’s Disease, and other cognitive disorders. Co-Chaired by: Jenny Laird, VP, Search & Evaluation Neuroscience, Eli Lilly and Company Sumant Kulkarni, Managing Director, Biotechnology Equity Research, Canaccord Genuity - Global Capital Markets Panellists: Alexander Gebauer, Co-Founder & Executive Chairman, Galimedix Therapeutics, Inc. Christian Howell, CEO, Cognito Therapeutics, Inc. Gaia Skibinski, Director of Discovery & Translation, The Michael J. Fox Foundation for Parkinson's Research Lisa Ricciardi, President & CEO, Cognition Therapeutics, Inc. Sander van Deventer, CEO, VectorY This panel will delve into the latest breakthroughs and strategies in managing and treating cognitive disorders, with a focus on Alzheimer’s and Parkinson’s diseases. Engage with top scientists and clinicians as they discuss new diagnostic tools, therapeutic approaches, and ongoing research that promises to transform patient outcomes. Don’t miss this opportunity to connect with leading minds in neurology and geriatrics. Secure your spot today at https://lnkd.in/dHgcp4fq and join us, both #inperson & #online, for a critical look at the future of cognitive disorder treatment. #AlzheimersResearch #ParkinsonsDisease #CognitiveHealth #Neuroscience #MedicalInnovation #NeurodegenerativeDiseases

Cognito Therapeutics is a late-stage clinical neurotechnology company pioneering disease-modifying treatments for neurodegenerative diseases. Its lead product, Spectris™, uses non-invasive auditory and visual neuromodulation to enhance gamma frequency brain activity, with the goal of slowing brain atrophy and functional decline in Alzheimer's disease. Cognito is committed to developing transformative, technology-driven interventions to address unmet needs in the treatment of CNS diseases. Cognito is headquartered in Cambridge, MA. Meet Cognito Therapeutics, Inc. @ #Sachs_NIF More Info @ https://lnkd.in/dHgcp4fq #Neuroscience #Neurotech #NeurologyInnovation #BrainHealth #CNSDisorders #NeurologicalDiseases #ADPD #Neuropsychiatry #PsychedelicResearch #NeuroTechInvestment #Biotech #MedicalInnovation #NeuroscienceForum #NeuroInvestment #NextGenMedicine #NeuroscienceResearch #MentalHealthInnovation #BiotechIndustry